Invenomic Capital Management LP Has $47.95 Million Stock Position in Acadia Healthcare Company, Inc. $ACHC

Invenomic Capital Management LP raised its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 41.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,936,396 shares of the company’s stock after acquiring an additional 568,796 shares during the period. Acadia Healthcare comprises about 2.3% of Invenomic Capital Management LP’s investment portfolio, making the stock its 5th largest position. Invenomic Capital Management LP’s holdings in Acadia Healthcare were worth $47,945,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Wellington Management Group LLP boosted its stake in shares of Acadia Healthcare by 11.8% in the 3rd quarter. Wellington Management Group LLP now owns 9,423,548 shares of the company’s stock valued at $233,327,000 after purchasing an additional 993,205 shares in the last quarter. Vanguard Group Inc. grew its stake in Acadia Healthcare by 7.8% during the third quarter. Vanguard Group Inc. now owns 9,417,045 shares of the company’s stock worth $233,166,000 after buying an additional 681,278 shares during the last quarter. Abrams Bison Investments LLC grew its stake in Acadia Healthcare by 22.3% during the third quarter. Abrams Bison Investments LLC now owns 4,380,000 shares of the company’s stock worth $108,449,000 after buying an additional 800,000 shares during the last quarter. UBS Group AG increased its holdings in shares of Acadia Healthcare by 8.8% during the third quarter. UBS Group AG now owns 4,336,698 shares of the company’s stock worth $107,377,000 after buying an additional 350,484 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Acadia Healthcare by 3.2% in the second quarter. State Street Corp now owns 3,095,775 shares of the company’s stock valued at $70,243,000 after acquiring an additional 95,670 shares during the last quarter.

Acadia Healthcare Price Performance

ACHC opened at $23.52 on Monday. The company has a fifty day moving average price of $16.80 and a two-hundred day moving average price of $18.73. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.55 and a current ratio of 1.55. The firm has a market capitalization of $2.17 billion, a PE ratio of -1.93, a P/E/G ratio of 7.95 and a beta of 0.73. Acadia Healthcare Company, Inc. has a 52 week low of $11.43 and a 52 week high of $31.04.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.04. Acadia Healthcare had a positive return on equity of 6.53% and a negative net margin of 33.29%.The business had revenue of $821.46 million for the quarter, compared to analyst estimates of $800.10 million. During the same period last year, the company earned $0.64 EPS. The firm’s revenue was up 6.1% on a year-over-year basis. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. As a group, analysts anticipate that Acadia Healthcare Company, Inc. will post 3.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ACHC. KeyCorp dropped their price target on Acadia Healthcare from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, December 3rd. Raymond James Financial restated an “outperform” rating and issued a $25.00 price objective on shares of Acadia Healthcare in a research report on Thursday, February 26th. Weiss Ratings reissued a “sell (d)” rating on shares of Acadia Healthcare in a research note on Wednesday, January 21st. Mizuho decreased their price objective on Acadia Healthcare from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, December 18th. Finally, TD Cowen boosted their target price on Acadia Healthcare from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $21.15.

Acadia Healthcare Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.